Developer docs
API playgroundTry for free, no card

Search company profiles

Liom

Full company profile

uuid0000lj8

Namestring
Liom
Legal namestring
Liom Health AG
Websiteurl
liom.com
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPfäffikon, Switzerland
HQ citystring
Pfäffikon
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive glucose monitoring, wearable health devices, Raman spectroscopy biosensors, continuous biomarker monitoring, consumer medical wearables
Industry2 codes
PRIMARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYCRACAIAF
Health Monitoring Wearables (ECG, BP, SpO2, CGM-compatible)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals334515
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Instruments For Meas & Testing Of Electricity & Elec Signals3825
Product category
Wearable Health Monitoring Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Wearable Device Sales
TypeHardware Sales
Description

Sale of non-invasive glucose monitoring wearable device to consumers and athletes

liom.com
2Health Data Subscription Services
TypeSubscription Recurring
Description

Potential recurring revenue from ongoing health monitoring, predictive alerts, meal optimization, and time-in-range analytics services

liom.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Liom develops a non-invasive, calibration-free wearable device that monitors glucose and other biomarkers continuously using a proprietary miniaturized Raman spectroscopy platform. The smartwatch-sized wearable analyzes light scattering at the wrist to deliver needle-free glucose readings alongside broader metabolic, fitness, cardiovascular, sleep, and mental wellness metrics, with planned commercial launch in 2028.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Continuous glucose monitoring without skin piercing - world first
+2 more records
Product overview1 text field

Liom offers a unified health wearable platform centered on its non-invasive glucose monitoring device. The core product is a Raman spectroscopy-based wearable that provides calibration-free, needle-free glucose measurements integrated with broader health metrics. The platform architecture includes multiple monitoring modules: Metabolic (continuous glucose monitoring with predictive alerts and meal optimization), Fitness (activity tracking and metabolic burn analysis), Cardiovascular (heart rate, variability, respiratory rate), Sleep (quality analysis and stages), and Mental (focus, energy, and stress tracking). Previously operated under the brand name 'Spiden' before rebranding to Liom in July 2024.

Product and service1 record
1Liom Non-Invasive Glucose Monitoring Wearable
CategoryWearable Health Monitoring Device
Description

A smartwatch-sized wearable device that uses proprietary miniaturized Raman spectroscopy to monitor glucose levels non-invasively through light scattering analysis at the wrist, without needles, skin piercing, or calibration. Designed for health-conscious consumers and athletes, with planned commercial launch in 2028.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Reportedly investing heavily in non-invasive glucose monitoring as a future Apple Watch feature. While not yet shipping, Apple represents the most consequential potential entrant: massive R&D budget, established consumer wearable distribution, and brand power could compress Liom's addressable market if launched before 2028.

TypeDirect peer
Description

U.S.-based developer of non-invasive glucose monitoring using radio frequency spectroscopy (BodyTell/KnowU). Direct competitor pursuing a needle-free, calibration-light glucose solution; a relevant technology alternative and competitive threat in the non-invasive CGM space.

TypeBroad incumbent
Description

Global medical device incumbent offering the Guardian CGM system as part of its insulin pump ecosystem. Relevant competitor in glucose monitoring with established payor and clinician channels; less direct overlap with Liom's non-invasive approach but defines the integrated diabetes care landscape.

TypeBroad incumbent
Description

Market leader in continuous glucose monitoring with the G6/G7 product lines. Directly competes with Liom in glucose monitoring but uses an invasive under-skin sensor rather than Liom's non-invasive optical approach. As an established, FDA-cleared CGM incumbent, it defines the accuracy and clinical workflow benchmark Liom must meet.

TypeEmerging player
Description

Consumer wearable (M1 glucose monitor / Ring) company selling continuous glucose monitoring and metabolic insights to health-conscious consumers and athletes — a very close comparable on go-to-market (DTC, athletes, metabolic optimization), although it currently relies on Abbott CGM sensors rather than proprietary non-invasive hardware.

TypeOthers
Description

Subscription-based metabolic health platform built on top of existing CGM sensors, providing insights to consumers. Comparable as a metabolic health subscription business model, but does not develop hardware and currently depends on incumbent CGM devices.

TypeEmerging player
Description

Public health-tech company developing the Evie Ring and related wearable health monitors, including blood pressure and metabolic signals. Comparable as a smaller wearable health device company pursuing multi-metric monitoring, though currently focused on different biomarkers than Liom.

TypeBroad incumbent
Description

World's largest CGM franchise with the Freestyle Libre series. Competes directly with Liom in glucose monitoring via a needle-based patch sensor. Abbott's scale, payor relationships, and established brand make it the primary entrenched competitor Liom must displace in the consumer glucose category.

TypeDirect peer
Description

Developer of the Eversense implantable CGM with 6-month sensor duration. Directly comparable as a glucose monitoring technology challenger targeting improved user experience over incumbents; though invasive, it represents an alternative approach to Liom's non-invasive wearable.

TypeEmerging player
Description

Developer of needle-free biosensor patches for continuous metabolic monitoring. Closely comparable to Liom in target market (glucose/metabolic monitoring) and product vision (a small wearable patch), though using electrochemical biosensors rather than optical spectroscopy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Liom

Wearable Health Monitoring Devicesliom.com

Liom firmographics

Firmographics
Name
Liom
Legal name
Liom Health AG
Website
https://liom.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Liom industry classification

Industry
Product category
Wearable Health Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Instruments For Meas & Testing Of Electricity & Elec Signals (3825)
akta.pro industry
PRIMARYCRACAQAE
Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYCRACAIAF
Health Monitoring Wearables (ECG, BP, SpO2, CGM-compatible)

Keywords

  • Non-invasive glucose monitoring
  • Wearable health devices
  • Raman spectroscopy biosensors
  • Continuous biomarker monitoring
  • Consumer medical wearables

Where Liom is headquartered

Location

Headquarters

HQ city
Pfäffikon
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Liom business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Wearable Device Sales: Sale of non-invasive glucose monitoring wearable device to consumers and athletes
  2. Health Data Subscription Services: Potential recurring revenue from ongoing health monitoring, predictive alerts, meal optimization, and time-in-range analytics services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Liom product offering

Product offering

Core offering

Liom develops a non-invasive, calibration-free wearable device that monitors glucose and other biomarkers continuously using a proprietary miniaturized Raman spectroscopy platform. The smartwatch-sized wearable analyzes light scattering at the wrist to deliver needle-free glucose readings alongside broader metabolic, fitness, cardiovascular, sleep, and mental wellness metrics, with planned commercial launch in 2028.

Product overview

Liom offers a unified health wearable platform centered on its non-invasive glucose monitoring device. The core product is a Raman spectroscopy-based wearable that provides calibration-free, needle-free glucose measurements integrated with broader health metrics. The platform architecture includes multiple monitoring modules: Metabolic (continuous glucose monitoring with predictive alerts and meal optimization), Fitness (activity tracking and metabolic burn analysis), Cardiovascular (heart rate, variability, respiratory rate), Sleep (quality analysis and stages), and Mental (focus, energy, and stress tracking). Previously operated under the brand name 'Spiden' before rebranding to Liom in July 2024.

Differentiator

Problem solved

Functional benefit

Products and services

  • Liom Non-Invasive Glucose Monitoring Wearable A smartwatch-sized wearable device that uses proprietary miniaturized Raman spectroscopy to monitor glucose levels non-invasively through light scattering analysis at the wrist, without needles, skin piercing, or calibration. Designed for health-conscious consumers and athletes, with planned commercial launch in 2028.

Quantifiable outcome

  • Continuous glucose monitoring without skin piercing - world first
  • +2 more outcomes

Companies that use Liom

Customer profile

Segments3 records

Ideal customer profiles2 records

Liom technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Liom partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Liom competitors and assessment

Company assessment

Broad incumbents

  • Apple: Reportedly investing heavily in non-invasive glucose monitoring as a future Apple Watch feature. While not yet shipping, Apple represents the most consequential potential entrant: massive R&D budget, established consumer wearable distribution, and brand power could compress Liom's addressable market if launched before 2028.
  • Medtronic Diabetes: Global medical device incumbent offering the Guardian CGM system as part of its insulin pump ecosystem. Relevant competitor in glucose monitoring with established payor and clinician channels; less direct overlap with Liom's non-invasive approach but defines the integrated diabetes care landscape.
  • Dexcom: Market leader in continuous glucose monitoring with the G6/G7 product lines. Directly competes with Liom in glucose monitoring but uses an invasive under-skin sensor rather than Liom's non-invasive optical approach. As an established, FDA-cleared CGM incumbent, it defines the accuracy and clinical workflow benchmark Liom must meet.
  • Abbott Diabetes Care (Freestyle Libre): World's largest CGM franchise with the Freestyle Libre series. Competes directly with Liom in glucose monitoring via a needle-based patch sensor. Abbott's scale, payor relationships, and established brand make it the primary entrenched competitor Liom must displace in the consumer glucose category.

Direct peers

  • Know Labs: U.S.-based developer of non-invasive glucose monitoring using radio frequency spectroscopy (BodyTell/KnowU). Direct competitor pursuing a needle-free, calibration-light glucose solution; a relevant technology alternative and competitive threat in the non-invasive CGM space.
  • Senseonics (Eversense): Developer of the Eversense implantable CGM with 6-month sensor duration. Directly comparable as a glucose monitoring technology challenger targeting improved user experience over incumbents; though invasive, it represents an alternative approach to Liom's non-invasive wearable.

Emerging players

  • Ultrahuman: Consumer wearable (M1 glucose monitor / Ring) company selling continuous glucose monitoring and metabolic insights to health-conscious consumers and athletes — a very close comparable on go-to-market (DTC, athletes, metabolic optimization), although it currently relies on Abbott CGM sensors rather than proprietary non-invasive hardware.
  • Movano Health: Public health-tech company developing the Evie Ring and related wearable health monitors, including blood pressure and metabolic signals. Comparable as a smaller wearable health device company pursuing multi-metric monitoring, though currently focused on different biomarkers than Liom.
  • Biolinq: Developer of needle-free biosensor patches for continuous metabolic monitoring. Closely comparable to Liom in target market (glucose/metabolic monitoring) and product vision (a small wearable patch), though using electrochemical biosensors rather than optical spectroscopy.

Others

  • Levels Health: Subscription-based metabolic health platform built on top of existing CGM sensors, providing insights to consumers. Comparable as a metabolic health subscription business model, but does not develop hardware and currently depends on incumbent CGM devices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Liom social profiles

Digital presence

Liom compliance and trust

Trust signal

Compliance1 record

Liom financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Liom leadership team

Management profile

Number of profiles

Profiles6 records

Liom funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Liom M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liom

What does Liom do?

Liom develops a non-invasive, calibration-free wearable device that monitors glucose and other biomarkers continuously using a proprietary miniaturized Raman spectroscopy platform. The smartwatch-sized wearable analyzes light scattering at the wrist to deliver needle-free glucose readings alongside broader metabolic, fitness, cardiovascular, sleep, and mental wellness metrics, with planned commercial launch in 2028.

Is Liom a public or private company?

Liom is a private company. It is classified as venture growth investor backed and is currently operating.

When was Liom founded?

Liom was founded in 2021. It employs 51 to 100 people.

Where is Liom based?

Liom is headquartered in Pfäffikon, Switzerland, in the Europe region.

How does Liom make money?

Two revenue lines are on record. Wearable Device Sales are the primary driver. The others are health Data Subscription Services.

Who are Liom's main competitors?

Broad incumbents on record are Apple, Medtronic Diabetes, Dexcom and Abbott Diabetes Care (Freestyle Libre). Direct peers are Know Labs and Senseonics (Eversense). Emerging players are Ultrahuman, Movano Health and Biolinq. Levels Health is listed as an others.

Does Liom have an API?

No public API is recorded for Liom.

What industry is Liom in?

Liom's product category is Wearable Health Monitoring Devices. Its primary akta.pro industry code is CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers), with a secondary code of CRACAIAF, Health Monitoring Wearables (ECG, BP, SpO2, CGM-compatible). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
eeNews EuropeFast Forward Awards 2026: HCP Sense, DeepGate, Myvox and LIOMHCP Sense, DeepGate, Myvox, and LIOM won the Fast Forward Awards 2026 at electronica in Munich on 13 November. The winners were recognized for industrial condition monitoring, embedded AI, MEMS cooling, and non-invasive health monitoring, with prizes totaling €100,000 in media support.startupticker.chExecutive reshuffles in diverse startupsLeadership changes at Nouscom, Oculus, Smart Energy Link, Rheo, and Liom include promotions and new appointments. Nouscom promoted Loredana Siani to CTO, Oculus appointed Björn Tackenberg as CSO, Smart Energy Link named Beat Scheurer CEO, Rheo appointed Guy Spörri CEO, and Liom added Vesa Mannisto as supply chain chief. These moves support growth amid positive development.eeNews EuropeLuchrome, BTRY, YPlasma, LIOM: Fast Forward Startups #1Elektor will host a free live discussion on 15 October 2026 featuring Luchrome, BTRY, YPlasma, and LIOM, covering printed displays, solid-state batteries, cooling, and health monitoring. The startups present their technologies, with BTRY having secured $5.7 million in seed funding. The event precedes electronica 2026.startupticker.chFive startups add key executive appointments to support growthFive startups—Luminarity, Dufour Aerospace, Amela Biosciences, LIOM, and GlycoEra—announced new executive appointments to support growth. Luminarity appointed Ulrich Amberg as CEO, Dufour Aerospace named Timon Wehmann co-CEO, Amela Biosciences hired Burak Ozan as CTO, LIOM added Mieko Kusano as CPO, and GlycoEra appointed Andrea Matthews as CBO.VentureRadarNew Funding Rounds in continuous glucoseMultiple health technology companies in the biomedical and digital health sectors have raised significant venture funding rounds, including Oviva AG, Vicentra, Liom Health AG, among others. These rounds aim to expand their healthcare solutions, ranging from AI-powered diagnostics to gene therapies and wearable biosensors.Longevity.TechnologyNon-invasive biomarker monitoring startup lands more fundingSwiss healthtech startup Liom secured a $16.5 million extension to its Series A financing, bringing the round total to $48 million and overall funding to $80 million, following a miniaturization breakthrough in its non-invasive glucose monitoring technology. The company aims for a commercial launch in 2028 with a smartwatch-sized device using Raman spectroscopy, initially targeting the European market before seeking medical clearance in Europe and the United States.startupticker.ch€13.9 million for glucose-monitoring wearableLiom secured an additional €13.9 million in its Series A extension round, bringing its total funding to CHF 63 million to support product development for a non-invasive glucose-monitoring wearable anticipated for launch in 2028. The company also appointed Marc Maurer, former co-CEO of On Running, to its board as part of the financing deal which included participation from Red Bull Ventures and other investors.FoundersTodayLiom extends Series A with €13.9M to advance Non-Invasive Glucose MonitoringSwiss HealthTech company Liom has secured €13.9 million as an extension to its Series A funding round, bringing total Series A financing to €40.8 million and total capital raised to €67.6 million, with new investors including Red Bull Ventures joining existing backers. The funding validates the company's scientific approach and accelerates development of its non-invasive glucose-monitoring wearable, which recently achieved a major technical milestone by miniaturising its Raman spectroscopy platform for smartwatch-sized hardware. Liom plans to use the proceeds to prepare for large-scale manufacturing and advance toward regulatory and commercial milestones, with its first product expected in 2028.Tech Funding NewsCan Liom’s needle‑free glucose wearable disrupt the Apple Watch era? — TFNLiom, a HealthTech startup from Schwyz, is developing a needle-free glucose-monitoring wearable and has extended its Series A funding by €13.9 million, bringing the total to €67.6 million. The new financing will support the company's transition from research and development to full product development and regulatory approval. With the aim to rival established wearable brands like the Apple Watch, Liom focuses on providing continuous, non-invasive glucose monitoring using advanced light-based technology.BebeezSwiss wearable glucose-monitoring technology startup Liom closes €13.9 million round – BeBeez InternationalSwiss HealthTech startup Liom announced a €13.9 million extension of its Series A financing round, bringing total Series A to €40.8 million and total funding to date to €67.6 million, with new participation from Red Bull Ventures and other investors including Marc Maurer, former co-CEO of On Running. The company has achieved a miniaturization breakthrough in its calibration-free Raman spectroscopy platform for non-invasive glucose monitoring, proven on over 130 subjects, and expects to launch its first wearable product in 2028.